Scholarlink

Background <p>Rheumatoid arthritis (RA) is a chronic immune-mediated synovial disease in which fibroblast-like synoviocytes (FLSs) exhibit a tumor-like phenotype that drives cartilage erosion and inflammation. Although MAF BZIP Transcription Factor F (MAFF) has been implicated in RA, its functional role in RA-FLSs remains unclear.</p> Methods <p>MAFF expression was examined in synovial tissues from RA and osteoarthritis (OA) patients using immunohistochemistry, western blotting, and qRT-PCR. Gain- and loss-of-function experiments were performed in primary RA-FLSs and MH7A cells via lentiviral-mediated overexpression or siRNA/shRNA-mediated knockdown. The involvement of NF-κB signaling was evaluated by western blot and by rescue experiments using the NF-κB inhibitor and agonist. The therapeutic potential of MAFF knockdown was evaluated in a mouse model.</p> Results <p>MAFF expression was significantly upregulated in RA-FLSs. Functional studies revealed that MAFF overexpression enhanced migration, invasion, and IL-6 production in RA-FLSs, while MAFF knockdown suppressed these pathogenic phenotypes. Mechanistically, MAFF activated the NF-κB pathway. MAFF expression was induced by TNF-α stimulation, and MAFF was required for TNF-α-induced NF-κB activation and functional responses. In vivo, intra-articular delivery of MAFF siRNA ameliorated arthritis severity, reduced inflammatory cell infiltration, preserved cartilage integrity, and protected against bone erosion in collagen-induced arthritis mice, effects that were partially reversed by PMA treatment.</p> Conclusions <p>MAFF is upregulated in RA and functions as a critical downstream mediator of TNF-α-induced NF-κB activation, promoting the aggressive phenotype of RA-FLSs. Targeting MAFF may represent a novel therapeutic strategy for ameliorating joint inflammation and destruction in RA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MAFF is a critical mediator of TNF-α-induced NF-κB activation and aggressive phenotype in rheumatoid arthritis synoviocytes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月1日

查看全文
  • Lijuan Qiu,
  • Yazhu Xu,
  • Tong Zhang,
  • An Wan,
  • Jinhui Tao

摘要

Background

Rheumatoid arthritis (RA) is a chronic immune-mediated synovial disease in which fibroblast-like synoviocytes (FLSs) exhibit a tumor-like phenotype that drives cartilage erosion and inflammation. Although MAF BZIP Transcription Factor F (MAFF) has been implicated in RA, its functional role in RA-FLSs remains unclear.

Methods

MAFF expression was examined in synovial tissues from RA and osteoarthritis (OA) patients using immunohistochemistry, western blotting, and qRT-PCR. Gain- and loss-of-function experiments were performed in primary RA-FLSs and MH7A cells via lentiviral-mediated overexpression or siRNA/shRNA-mediated knockdown. The involvement of NF-κB signaling was evaluated by western blot and by rescue experiments using the NF-κB inhibitor and agonist. The therapeutic potential of MAFF knockdown was evaluated in a mouse model.

Results

MAFF expression was significantly upregulated in RA-FLSs. Functional studies revealed that MAFF overexpression enhanced migration, invasion, and IL-6 production in RA-FLSs, while MAFF knockdown suppressed these pathogenic phenotypes. Mechanistically, MAFF activated the NF-κB pathway. MAFF expression was induced by TNF-α stimulation, and MAFF was required for TNF-α-induced NF-κB activation and functional responses. In vivo, intra-articular delivery of MAFF siRNA ameliorated arthritis severity, reduced inflammatory cell infiltration, preserved cartilage integrity, and protected against bone erosion in collagen-induced arthritis mice, effects that were partially reversed by PMA treatment.

Conclusions

MAFF is upregulated in RA and functions as a critical downstream mediator of TNF-α-induced NF-κB activation, promoting the aggressive phenotype of RA-FLSs. Targeting MAFF may represent a novel therapeutic strategy for ameliorating joint inflammation and destruction in RA.